Publication | Open Access

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

AllergyAtopic DermatitisMedicineAllergy MedicineModerate-to-severe Atopic DermatitisClinical TrialsSkin AllergyClinical DermatologyJade Mono-1PharmacotherapyDermatologyDrug Allergy